Deciphera Pharmaceuticals, Inc. Overview
Pro stress-test →Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. The company leverages its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In April 2024, ONO Pharmaceutical Company acquired all outstanding shares of Deciphera for $25.60 per share in cash, for a total equity value of $2.4 billion.
Strategic Profile
Pro stress-test →The lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company has the potential to reach $1 billion in peak revenue with QINLOCK and vimseltinib, establishing itself as a multi-product commercial-stage enterprise.
Competitive Landscape
Pro stress-test →Deciphera competes in the kinase inhibitor oncology space against established players including Novartis (Gleevec, Tasigef), Pfizer (Sutent), and other targeted cancer therapy developers. The company's switch-control kinase platform and focused pipeline on GIST and other solid tumors differentiate it from broader-spectrum oncology competitors. Post-acquisition by ONO Pharmaceutical, Deciphera gains access to greater global distribution and combined R&D capabilities.
Industry Context
Deciphera Pharmaceuticals, Inc. operates in Biopharmaceuticals (Oncology).
Key facts
Founded: 2003 · Headquarters: Waltham, MA, US · Employees: 501-1,000 · Revenue: ~$46.0M (Q4 2023 QINLOCK alone) · Market cap: N/A